Enrofloxacin + Ketoconazole + Triamcinolone + Silver Sulfadazine + Tobramycin + Polymixin B
14 adverse event reports submitted to the FDA
Active Ingredients
Administration Routes
Species Affected
Most Affected Breeds
Most Reported Reactions
Outcome Breakdown
Data Summary
| Metric | Value |
|---|---|
| Total adverse event reports | 14 |
| Reports involving death | 0 |
| Case-fatality rate (reported events) | 0.0% |
| Distinct species in reports | 2 |
| Distinct breeds in reports | 11 |
| Distinct reactions reported | 20 |
| Active ingredients on file | 1 |
Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.
Enrofloxacin + Ketoconazole + Triamcinolone + Silver Sulfadazine + Tobramycin + Polymixin B Adverse Event Insights
The FDA Center for Veterinary Medicine database currently holds 14 adverse event reports referencing Enrofloxacin + Ketoconazole + Triamcinolone + Silver Sulfadazine + Tobramycin + Polymixin B, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Enrofloxacin + Ketoconazole + Triamcinolone + Silver Sulfadazine + Tobramycin + Polymixin B. Reported administration routes include Auricular (Otic), Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.
The species most frequently named in Enrofloxacin + Ketoconazole + Triamcinolone + Silver Sulfadazine + Tobramycin + Polymixin B reports are Dog (13 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (3), Spaniel - Cocker American (2), Retriever - Golden (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.
The most commonly reported clinical signs associated with Enrofloxacin + Ketoconazole + Triamcinolone + Silver Sulfadazine + Tobramycin + Polymixin B are Lack of efficacy - NOS (4), Emesis (3), Weight loss (3), Vomiting (3). Of the 14 reports with a coded outcome, Outcome Unknown is the leading category at 42.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Enrofloxacin + Ketoconazole + Triamcinolone + Silver Sulfadazine + Tobramycin + Polymixin B.
Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates
Read our methodology — how this data is sourced, computed, and verified.